Neuvasq was pleased to participate in the ARVO 2025 Annual Meeting, held from May 4–8 in Salt Lake City, where the company presented recent progress in its blood-retina barrier (BRB) research.
During a poster session on Monday, May 8, Neuvasq’s Chief Scientific Officer Ralph Laufer and Head of Discovery Marc Vanhove shared in vitro and in vivo data on the company’s lead candidate: a Wnt surrogate antibody targeting the BRB. This antibody has been developed using Neuvasq’s proprietary platform that modulates Gpr124 and Reck, two essential co-factors in Wnt/β-catenin signaling.
The presented findings highlight the therapeutic potential of Neuvasq’s approach in restoring BRB integrity in vascular retinopathies, including diabetic macular edema (DME) and wet age-related macular degeneration (wAMD).
This event provided an opportunity to engage with the ophthalmology research community and to discuss the promise of Wnt-based biologics in addressing unmet medical needs in retinal vascular disorders.
Neuvasq remains committed to advancing science-driven solutions in neurovascular health.
Cookie policy